Payment overview · 2025
General Payments
$269.31
14 reported records · 4 companies
Healthcare provider profile · identity verified
Todd A Mccaslin, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · IMPERIAL, PA · NPI 1285656041
Verified facts
What the public records show
CMS Open Payments records show Todd A Mccaslin, M.D. received $269.31 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 58.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 125 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $157.40 | 58.5% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.31 | 26.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.27 | 8.3% | 1 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $17.33 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $269.31 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $99.91 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $57.49 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.51 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.80 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $26.14 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.78 | 1 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 125 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
113 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
114 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
125 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 742 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 610 | 180 |
| Levothyroxine Sodium | Levothyroxine Sodium | 588 | 147 |
| Gabapentin | Gabapentin | 472 | 107 |
| Omeprazole | Omeprazole | 466 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 382 | 103 |
| Lisinopril | Lisinopril | 370 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 317 | 79 |
| Metformin Hcl | Metformin Hcl | 299 | 79 |
| Ezetimibe | Ezetimibe | 298 | 81 |
| Losartan Potassium | Losartan Potassium | 297 | 87 |
| Pravastatin Sodium | Pravastatin Sodium | 287 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 262 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 230 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 225 | 59 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 221 | 31 |
| Furosemide | Furosemide | 216 | 56 |
| Simvastatin | Simvastatin | 216 | 66 |
| Alprazolam | Alprazolam | 197 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 190 | 49 |
| Spironolactone | Spironolactone | 186 | 51 |
| Allopurinol | Allopurinol | 183 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 170 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 168 | 44 |
| Eliquis | Apixaban | 162 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 155 | 43 |
| Sertraline Hcl | Sertraline Hcl | 154 | 39 |
| Montelukast Sodium | Montelukast Sodium | 151 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 94 |
| Bupropion Hcl Sr | Bupropion Hcl | 139 | 39 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 134 | 38 |
| Atenolol | Atenolol | 130 | 37 |
| Mirtazapine | Mirtazapine | 129 | 25 |
| Ozempic | Semaglutide | 125 | 24 |
| Glimepiride | Glimepiride | 121 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 116 | 37 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 114 | 21 |
| Potassium Chloride | Potassium Chloride | 113 | 31 |
| Synthroid | Levothyroxine Sodium | 113 | 30 |
| Donepezil Hcl | Donepezil Hcl | 111 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 107 | 25 |
| Telmisartan | Telmisartan | 105 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 98 | 92 |
| Xarelto | Rivaroxaban | 95 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 92 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 29 |
| Trazodone Hcl | Trazodone Hcl | 89 | 23 |
| Valsartan | Valsartan | 89 | 22 |
| Tramadol Hcl | Tramadol Hcl | 87 | 21 |
| Lorazepam | Lorazepam | 85 | 26 |
| Meloxicam | Meloxicam | 81 | 30 |
| Glipizide Er | Glipizide | 79 | 18 |
| Methylprednisolone | Methylprednisolone | 79 | 64 |
| Januvia | Sitagliptin Phosphate | 78 | 17 |
| Clonazepam | Clonazepam | 75 | 17 |
| Metformin Hcl Er | Metformin Hcl | 71 | 16 |
| Finasteride | Finasteride | 67 | 16 |
| Buspirone Hcl | Buspirone Hcl | 65 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 16 |
| Alendronate Sodium | Alendronate Sodium | 63 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 18 |
| Carvedilol | Carvedilol | 60 | 21 |
| Warfarin Sodium | Warfarin Sodium | 60 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 57 | suppressed |
| Ibuprofen | Ibuprofen | 56 | 25 |
| Prednisone | Prednisone | 56 | 27 |
| Tradjenta | Linagliptin | 54 | 12 |
| Irbesartan | Irbesartan | 53 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 51 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 13 |
| Colestipol Hcl | Colestipol Hcl | 48 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 40 |
| Colchicine | Colchicine | 42 | 11 |
| Famotidine | Famotidine | 42 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 42 | 11 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 12 |
| Celecoxib | Celecoxib | 39 | 14 |
| Meclizine Hcl | Meclizine Hcl | 39 | 17 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | 13 |
| Sucralfate | Sucralfate | 38 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 25 |
| Glipizide | Glipizide | 36 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 36 | 14 |
| Azelastine Hcl | Azelastine Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 26 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 34 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 33 | 15 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 33 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Ondansetron Odt | Ondansetron | 28 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 20 |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Dutasteride | Dutasteride | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Nystatin | Nystatin | 21 | 15 |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Ibu | Ibuprofen | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Jantoven | Warfarin Sodium | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Asmanex | Mometasone Furoate | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $269.31 · 14 records | Novo Nordisk Inc | AREXVY, INNOVAMATRIX AC, Ozempic, QULIPTA, Rybelsus, SHINGRIX, UBRELVY, VRAYLAR, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error